Despite the introduction of new therapies such as the GLP-1 receptor agonists and SGLT2 inhibitors, many people with T2D do not meet the recommended glucose targets and still require insulin to manage their diabetes [96]. This evidence concerns the gene INS and type 2 diabetes mellitus.